LENZ Therapeutics, Inc. (NASDAQ: LENZ) entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO to register and commercialize its FDA‑approved presbyopia eye drop VIZZ in the Middle East. The partnership grants Lunatus exclusive rights to market VIZZ in the United Arab Emirates, Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon and Iraq, while LENZ will receive upfront, regulatory and commercial milestone payments and a share of regional revenue.
VIZZ, a 1.44% aceclidine ophthalmic solution, received FDA approval in July 2025 and became commercially available in the United States on September 30 2025. It is the first and only FDA‑approved aceclidine‑based eye drop that improves near vision for up to 10 hours with once‑daily use, filling a significant unmet need for presbyopia patients.
The agreement represents LENZ’s fourth commercialization partnership for VIZZ, following licensing deals in Greater China, Southeast Asia and Canada. By adding the Middle East to its portfolio, LENZ diversifies its revenue streams and reduces dependence on the U.S. market, positioning the company for sustained global growth.
The Middle East presbyopia market is projected to reach US$209.7 million by 2030, with limited treatment options currently available. Lunatus, founded in 2003 and headquartered in Dubai, has a proven track record of regulatory approvals and commercial launches across the Gulf and Arabian Gulf region, which should accelerate VIZZ’s market entry and adoption in the nine target countries.
While the specific financial terms of the deal are not disclosed, LENZ will receive upfront, regulatory and commercial milestone payments and a share of regional revenue, providing immediate cash‑flow benefits and a long‑term revenue stream as VIZZ gains market penetration.
Eef Schimmelpennink, President and CEO of LENZ, said the partnership “expands our global reach and leverages Lunatus’s strong regulatory and commercial capabilities in the Middle East, accelerating VIZZ’s availability to patients who need it.” Dr. Lina Kouatly, President & CEO of Lunatus, added that the collaboration “will bring a transformational eye‑care solution to a region with a growing unmet need for presbyopia.”
The deal underscores LENZ’s strategy to secure international licenses and distribution agreements to unlock VIZZ’s full commercial potential. Immediate milestone payments strengthen the company’s cash position, while the revenue‑sharing model aligns incentives for both parties and positions LENZ for long‑term growth in a high‑potential market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.